، صفحه 0-0 (1) اصل مقاله (364.6 K)

عنوان دوره: اولین دوره بین المللی و بیست و هشتمین دوره ملی (1400)

saeed kakaei؛ elham sattarzadeh؛ Seyed Mahmoudreza Aghamiri؛ yashar Noshadi؛ Hassan Yousefnia

Bone metastases are one of the main consequences of some cancers, such as breast, lung and prostate cancers, which are accompanied by severe pain in the bone area. Gallium-68 radioisotope with a half-life of 68 minutes is one of the most suitable options in Positron emission tomography (PET) is used in nuclear medicine. In this study, one of the zoledronic acid derivatives was synthesized as a bone-seeking agent and then attached to the DOTA chelator. The DOTA-ZOL compound was finally used for 68Ga labeling. All synthesized products were identified by FT-IR, NMR and MASS spectroscopies. The radiochemical purity of the final complex was examined by thin-layer chromatography technique. Radiochemical purity and yield of radiolabeling were determined about 97%. The results of this study showed that 68Ga-DOTA-ZOL is a suitable diagnostic radiopharmaceutical for imaging bone metastases by PET method.

68Ga؛ Labeled composition؛ PET؛ Zoledronic acid derivatives؛ Bone Metastases

<p>-1</p>